| 吴玲云,杨伟林.沙库巴曲缬沙坦治疗不同病因慢性心力衰竭患者的临床疗效差异研究[J].浙江中西医结合杂志,2024,34(10): |
| 沙库巴曲缬沙坦治疗不同病因慢性心力衰竭患者的临床疗效差异研究 |
| Study on the clinical efficacy differences of Sacubitril/Valsartan in the treatment of patients with Chronic Heart Failure with different causes |
| 投稿时间：2023-05-21 修订日期：2024-09-08 |
| DOI： |
| 中文关键词: 沙库巴曲缬沙坦 慢性心力衰竭 不同病因 疗效差异 |
| 英文关键词:Sacubitril/Valsartan, Chronic Heart Failure, Different Etiologies , Differences in Efficacy |
| 基金项目:湖州市科学技术局研究项目（2020GY89）；浙江省中医药科技计划项目（2023ZL691） |
|
| 摘要点击次数: 383 |
| 全文下载次数: 6 |
| 中文摘要: |
| 目的：研究沙库巴曲缬沙坦在治疗不同病因所致的慢性心力衰竭患者中的临床疗效差异。方法：纳入2019年-2021年所收治的符合纳入标准的180例慢性心力衰竭患者，根据慢性心力衰竭的病因分为4组：扩张型心肌病组45例、冠心病组45例、高血压性心脏病组45例、瓣膜性心脏病组45例。在心衰标准化治疗基础之上，联合沙库巴曲缬沙坦治疗6月，通过研究治疗前后心衰患者的相关观察指标的变化，评估探析沙库巴曲缬沙坦治疗不同病因所致慢性心力衰竭患者的临床疗效差异。结果：1）各病因组患者年龄、性别及治疗前心衰观察指标均无明显差异（P>0.05）；2）沙库巴曲缬沙坦能够显著改善各病因组NT-proBNP、LVEDd、 LVEF、6min步行距离及明尼苏达心衰生活质量量表评分（P<0.05），但组间治疗差异不明显（P>0.05）；3）沙库巴曲缬沙坦治疗各病因组慢性心衰总体有效率无明显差异（P>0.05）；4) 心血管严重不良事件发生率为6.7%。结论：沙库巴曲缬沙坦对治疗不同病因的慢性心力衰竭患者的疗效显著，但各病因组间总体治疗效果差异不大。 |
| 英文摘要: |
| Objective: The aim of this research is to scrutinize the disparities in the clinical efficacy of Sacubitril/Valsartan when employed in the treatment of Chronic Heart Failure(CHF) patients, with diverse underlying causes. Methods: The study cohort comprised of 75 patients suffering from CHF, who received treatment during 2019-2020 and satisfied the stipulated inclusion parameters. These patients were sorted into four distinct categories based on the root cause of their Objective: The aim of this research is to scrutinize the disparities in the clinical efficacy of Sacubitril/Valsartan when employed in the treatment of Chronic Heart Failure(CHF) patients, with diverse underlying causes. Methods: The study cohort comprised of 180 patients suffering from CHF, who received treatment during 2019-2020 and satisfied the stipulated inclusion parameters. These patients were sorted into four distinct categories based on the root cause of their CHF: dilated cardiomyopathy (45 patients), coronary heart disease (45 patients), hypertensive heart disease (45 patients), and valvular heart disease (45patients). Alongside the established treatment regimen for heart failure, Sacubitril/Valsartan was administered over a period of 6 months. The alterations in various observational indicators for heart failure patients pre and post-treatment were studied to gauge the differential clinical efficacy of Sacubitril/Valsartan in managing CHF resulting from different etiologies. Results: 1) There were no significant discrepancies in age, gender, and heart failure observational indicators prior to treatment across all etiological groups (P>0.05); 2) Sacubitril/Valsartan notably enhanced NT-proBNP, LVEDd, LVEF, the 6-minute walking distance, and scores on the Minnesota Living with Heart Failure Questionnaire for each etiological group (P<0.05). However, no significant differences were observed in the treatment outcomes across the groups (P>0.05); 3) The overall effectiveness of Sacubitril/Valsartan in treating CHF showed no notable discrepancies across all etiological groups (P>0.05); 4) The incidence rate of severe cardiovascular adverse events stood at 6.7%. Conclusion: Sacubitril/Valsartan demonstrates significant therapeutic effectiveness for patients with CHF, irrespective of their condition's etiology. However, the overall treatment outcomes exhibit minimal variation among the diverse etiological groups. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
